Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Cancers
|
February 6, 2021
<i>TP53</i> Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients
Ritu Pandey, Nathan Johnson, Laurence Cooke, et al.
Journal of Ovarian Research
|
August 28, 2016
Genomic alterations in neuroendocrine cancers of the ovary
George Yaghmour, Philippe Prouet, Eric Wiedower, et al.
CNS Oncology
|
September 6, 2021
Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
Ngan Nguyen, Jordan Redfield, Matthew Ballo, et al.
Neuro-Oncology Advances
|
October 17, 2022
Determinants of tumor treating field usage in patients with primary glioblastoma: A single institutional experience
Matthew T Ballo, Kaitlin W Qualls, L Madison Michael, et al.
Breast Cancer Research and Treatment
|
June 23, 2016
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung
Brennan McCullar, Manjari Pandey, George Yaghmour, et al.
Breast Cancer Research and Treatment
|
October 12, 2018
Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung
Brennan McCullar, Manjari Pandey, George Yaghmour, et al.
Anticancer Research
|
July 29, 2016
Role of Genomic Instability in Immunotherapy with Checkpoint Inhibitors
George Yaghmour, Manjari Pandey, Catherine Ireland, et al.
JCO Precision Oncology
|
February 1, 2022
Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases
Matthew K Stein, Manjari Pandey, Joanne Xiu, et al.
Neuro-Oncology Advances
|
July 13, 2022
Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields
Manjari Pandey, Joanne Xiu, Sandeep Mittal, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2019
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
Daruka Mahadevan, Mark C Lanasa, Charles Farber, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Cancers
|
February 6, 2021
<i>TP53</i> Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients
Ritu Pandey, Nathan Johnson, Laurence Cooke, et al.
Journal of Ovarian Research
|
August 28, 2016
Genomic alterations in neuroendocrine cancers of the ovary
George Yaghmour, Philippe Prouet, Eric Wiedower, et al.
CNS Oncology
|
September 6, 2021
Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
Ngan Nguyen, Jordan Redfield, Matthew Ballo, et al.
Neuro-Oncology Advances
|
October 17, 2022
Determinants of tumor treating field usage in patients with primary glioblastoma: A single institutional experience
Matthew T Ballo, Kaitlin W Qualls, L Madison Michael, et al.
Breast Cancer Research and Treatment
|
June 23, 2016
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung
Brennan McCullar, Manjari Pandey, George Yaghmour, et al.
Breast Cancer Research and Treatment
|
October 12, 2018
Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung
Brennan McCullar, Manjari Pandey, George Yaghmour, et al.
Anticancer Research
|
July 29, 2016
Role of Genomic Instability in Immunotherapy with Checkpoint Inhibitors
George Yaghmour, Manjari Pandey, Catherine Ireland, et al.
JCO Precision Oncology
|
February 1, 2022
Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases
Matthew K Stein, Manjari Pandey, Joanne Xiu, et al.
Neuro-Oncology Advances
|
July 13, 2022
Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields
Manjari Pandey, Joanne Xiu, Sandeep Mittal, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2019
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
Daruka Mahadevan, Mark C Lanasa, Charles Farber, et al.
Page
of 3